Search
12 articles for “Anti-TB drugs”
-
Prevalence of Adverse Drug Reactions and Risk Factors Associated with first Line Anti- Tuberculosis Drugs
Abstract: Background: The recommended first line treatment of active tuberculosis (TB) consists of rifampicin (R), isoniazid (H), ethambutol (E) and pyrazinamide (Z). The regimen is highly effective in treating active TB however it is associated with various adverse drug reactions (ADRs) posing undeniable challenges to therapy success. Objectives: To determine the prevalence of ADRs and risk factors associated with first-line anti-tuberculosis medications. Methods: A quantitative cross-sectional descriptive study conducted at the …
Published in Research and Reviews: A Journal of Microbiology and Virology · Vol. 12, Issue 2, 2022 · pp. 9–16 Read article
-
Bedaquiline: An In-Depth Exploration into Its Antitubercular Significance
Abstract: Tuberculosis is still a leading infectious disease and a major threat to public health. Although there has been a slow decrease in the incidence over years, its “hard to kill nature” is responsible of about 2 million deaths in HIV infected individuals annually. Bedaquiline, a Diaryl-Quinoline drug was fast-track approved as an orphan drug to combat drug resistance. It shows potent activity against Mycobacterium tuberculosis by interfering with the production …
Published in Research & Reviews: A Journal of Drug Design & Discovery · Vol. 12, Issue 2, 2025 · pp. 06–14 Read article
-
Pharmacophore mapping, 3D QSAR, docking, and ADME prediction studies of novel Benzothiazinone derivatives
Abstract: Background Tuberculosis is a major public health concern worldwide which is caused by Mycobacterium tuberculosis. DprE1 (Decaprenyl Phosphoryl Ribose 2’- Epimerase) is the most challenging target for development of novel anti- tubercular agents because it is a small protein and located into cytoplasmic membrane. So, novel anti-TB drugs did not bound effectively with it. DprE1 catalyzes the oxidation of the 2’ hydroxyl group of DPR (Decaprenyl Phosphoryl D- Ribose) …
Published in International Journal of Antibiotics · Vol. 1, Issue 1, 2024 · pp. 59–82 Read article
-
Tuberculosis Treatment Outcomes among TB Patients at FenoteSelam District Hospital, West Gojjam Zone, Amhara, Northwest Ethiopia
Abstract: Introduction: Tuberculosis is a major public health problem throughout the world. One third of the world’s population is estimated to be infected with bacilli and hence at risk of developing active disease. It is the second leading cause of death from an infectious disease worldwide after HIV, which caused an estimated 1.8 million deaths. The main reason for this is the high rate of death as an unsuccessful outcome. Incomplete …
Published in Research and Reviews: A Journal of Medicine · Vol. 6, Issue 3, 2016 · pp. 1–8 Read article
-
Effect of Glycemic Control on Sputum Conversion at the End of Intensive Phase of Category I DOTS Therapy among Patients with Pulmonary Tuberculosis
Abstract: India is an endemic country of tuberculosis and diabetic capital of the world. A patient with diabetes has more chance of occurrence tuberculosis. Many studies pointed out the merging epidemic of diabetes and tuberculosis. Rifampicin and Isoniazid are the most prominent drugs in anti-TB treatment. These drugs disrupt the metabolism of many anti-hypoglycemic agents and lower the plasma levels, leading to hypogycemia. In non-diabetics, it impairs the release and action …
Published in Journal of Nursing Science & Practice · Vol. 10, Issue 1, 2020 · pp. 13–17 Read article
-
In-Silico Repurposing of Antipsychotic Drugs Against Novel Protein Targets in Multidrug-Resistant Mycobacterium tuberculosis
Abstract: Multidrug-resistant TB is a growing worldwide health concern, particularly in high-burden areas. Resistance to frontline drugs like isoniazid and rifampicin is caused by mutations in key Mycobacterium tuberculosis proteins. Given the difficulty of developing new antibiotics, medication repurposing offers a good alternative. The potential use of molecular docking to target resistance-associated TB proteins with FDA-approved antipsychotic drugs is investigated in this work. Three proteins were selected: InhA (PDB ID: 5W07), …
Published in Research & Reviews: A Journal of Drug Design & Discovery · Vol. 13, Issue 1, 2026 · pp. 49–63 Read article
-
Pathogenesis and Treatment of Tuberculosis (T.B) Disease
Abstract: Tuberculosis (TB) is an infectious illness spread through the air that is caused by organisms from the Mycobacterium tuberculosis complex. M. tuberculosis is a lung infection in primary stage, but it can infect any area of the body. M. tuberculosis infection can progress from latent TB infection, in which the bacteria are isolated within granulomas, to infectious infection, in which the patient develops symptoms such as cough, fever, night sweats, …
Published in Research and Reviews : A Journal of Immunology · Vol. 11, Issue 3, 2021 · pp. 42–48 Read article
-
Colorimetric Redox Indicator assay for rapid detection of multidrug-resistant Mycobacterium tuberculosis in South Gujarat region
Abstract: Tuberculosis (TB) has affected humans since antiquity. The burden of TB particularly with multi-drug-resistance (MDR) is increasing worldwide and has become a major public health concern. This study aims to perform Colorimetric Redox Indicator (CRI) assay for rapid detection of multidrug-resistant Mycobacterium tuberculosis in South Gujarat region. Total 234 samples were collected from South Gujarat region and were subjected for microscopy examination, culturing on Lowenstein-Jensen (LJ) medium and drug susceptibility …
Published in Research and Reviews: A Journal of Microbiology and Virology · Vol. 8, Issue 3, 2018 · pp. 65–70 Read article
-
Innovations in Tuberculosis Management: Advancements in Drug-Resistant TB Treatment and Rapid Diagnostics
Abstract: Tuberculosis (TB) remains one of the deadliest infectious diseases worldwide, exacerbated by the increasing prevalence of drug-resistant strains, such as multidrug-resistant (MDR-TB) and extensively drug-resistant TB (XDR-TB). Despite advancements in first-line and second-line treatments, resistance to conventional antibiotics has complicated therapeutic strategies, necessitating novel approaches. This mini review explores emerging advancements in TB treatment, including gene editing technologies, such as CRISPR, which offer potential for precise targeting of drug-resistant bacterial …
Published in International Journal of Antibiotics · Vol. 2, Issue 2, 2025 · pp. 1–7 Read article
-
In Silico Drug Design for Mycobacterium tuberculosis and Development of Host–Pathogen Interaction Network and Molecular Docking Procedures
Abstract: Objective: A leading cause of illness is the contagious disease tuberculosis (TB), this infection with Mycobacterium tuberculosis complex (MTBC) particularly M. tuberculosis and M. africanum, is what causes tuberculosis. Diverse receptor proteins (mycobacterial proteins) with various 3D structures and functions were evaluated to access the multi-domain antimycobacterial action of ligands. The specific receptor proteins PDB ID: 3PTY, PDB ID: 4OW8, PDB ID: 5KWA, and PDB ID: 3ZXR, were opted for …
Published in International Journal of Molecular Biotechnological Research · Vol. 1, Issue 1, 2023 · pp. 1–19 Read article
-
First Insights into Whole Genome Sequencing of the Mycobacterium tuberculosis Complex: Molecular Diversity and Drug Susceptibility Patterns in Senegal
Abstract: Background: We conducted a bibliographic analysis of the Mycobacterium tuberculosis complex (MTBC) in sub-Saharan Africa, which included the analysis of 8,139 genomic sequences from 34 of the 49 sub-Saharan African countries. Notably, only one complete sequence from Senegal was identified, which had been generated in the United States. Our primary objective was to utilize whole genome sequencing (WGS) to detect resistance in anti-tuberculous strains of the MTBC in Senegal. This …
Published in Recent Trends in Infectious Diseases · Vol. 2, Issue 1, 2025 Read article
-
Tuberculosis Epidemiology and its Diagnostic Modality
Abstract: Tuberculosis (TB) remains a global health emergency, with India being the epicenter, recording 2.23 million cases and approximately 4.53 lakhs deaths in 2021. Despite efforts by the National Tuberculosis Eradication Program (NTEP), the anticipated decrease in the incidence and prevalence of TB has not been actualized. This paper examines the persistently high rates of TB in India, identifying critical risk factors such as male gender, marital status, overcrowding, socioeconomic disadvantages, …
Published in Research and Reviews: A Journal of Microbiology and Virology · Vol. 13, Issue 3, 2023 · pp. 7–11 Read article